Inhibrx Biosciences, Inc.
INBX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002007919
In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 6 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Inhibrx Biosciences, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 126
- +15 vs. Q3 2023
- Shares held
- 40.6M
- +1.54M (+3.9%) vs. Q3 2023
- Total value
- $1.54B
- +$824.9M (+115.2%) vs. Q3 2023
- New holders
- 29
- 32 more added
- Sold out
- 14
- 43 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INBX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 162 | $1.36B |
| Q1 2026 | 135 | $854.6M |
| Q4 2025 | 138 | $1.01B |
| Q3 2025 | 102 | $353.6M |
| Q2 2025 | 89 | $148.9M |
| Q1 2025 | 92 | $151.0M |
| Q4 2024 | 101 | $171.9M |
| Q3 2024 | 96 | $139.3M |
| Q2 2024 | 88 | $137.9M |
| Q1 2024 | 126 | $1.34B |
| Q4 2023 | 126 | $1.54B |
| Q3 2023 | 111 | $716.1M |
| Q2 2023 | 107 | $935.2M |
| Q1 2023 | 108 | $691.6M |
| Q4 2022 | 116 | $886.0M |
| Q3 2022 | 102 | $512.2M |
| Q2 2022 | 100 | $297.3M |
| Q1 2022 | 99 | $548.0M |
| Q4 2021 | 101 | $1.01B |
| Q3 2021 | 66 | $681.6M |
| Q2 2021 | 61 | $538.8M |
| Q1 2021 | 55 | $326.3M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Inhibrx Biosciences, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Platinum Investment Management Ltd | 167,763 | $6.37M | 0.26% | −61,273−26.8% | Reduced |
| Two Sigma Advisers, LP | 210,800 | $8.01M | 0.02% | −99,400−32.0% | Reduced |
| Sphera Funds Management Ltd. | 226,551 | $8.61M | 1.60% | −29,820−11.6% | Reduced |
| Charles Schwab Investment Management Inc | 229,866 | $8.73M | 0.00% | +17,762+8.4% | Added |
| Citadel Advisors LLC | 254,838 | $9.68M | 0.01% | +12,028+5.0% | Added |
| Millennium Management LLC | 261,058 | $9.92M | 0.01% | +228,730+707.5% | Added |
| Morgan Stanley | 296,919 | $11.3M | 0.00% | −85,851−22.4% | Reduced |
| Northern Trust Corp | 313,889 | $11.9M | 0.00% | −1,529−0.5% | Reduced |
| Russell Investments Group, Ltd. | 435,450 | $16.5M | 0.03% | −23,606−5.1% | Reduced |
| PFM Health Sciences, LP | 537,964 | $20.4M | 1.23% | +249,347+86.4% | Added |
| Geode Capital Management, LLC | 687,360 | $26.1M | 0.00% | +41,201+6.4% | Added |
| Bank of America Corp | 692,980 | $26.3M | 0.00% | +577,231+498.7% | Added |
| Capital Research Global Investors | 712,360 | $27.1M | 0.01% | −509,361−41.7% | Reduced |
| Sofinnova Investments, Inc. | 772,957 | $29.4M | 1.65% | +29,663+4.0% | Added |
| ArrowMark Colorado Holdings LLC | 956,881 | $36.4M | 0.40% | −9,115−0.9% | Reduced |
| Loomis Sayles & Co L P | 1,082,225 | $41.1M | 0.06% | −34,259−3.1% | Reduced |
| FMR LLC | 1,469,909 | $55.9M | 0.00% | −47,686−3.1% | Reduced |
| Vestal Point Capital, LP | 1,530,000 | $58.1M | 6.16% | +1,530,000 | New |
| State Street Corp | 1,635,726 | $62.2M | 0.00% | +18,955+1.2% | Added |
| TCG Crossover Management, LLC | 1,750,387 | $66.5M | 7.38% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,874,323 | $71.2M | 0.00% | +84,512+4.7% | Added |
| Woodline Partners LP | 2,318,576 | $88.1M | 0.96% | +793,661+52.0% | Added |
| BlackRock Inc. | 2,715,672 | $103.2M | 0.00% | +175,899+6.9% | Added |
| Perceptive Advisors LLC | 4,256,104 | $161.7M | 3.62% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 4,724,207 | $179.5M | 2.80% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 7,150,826 | $271.7M | 1.00% | 00.0% | Unchanged |
| Eventide Asset Management, LLC | 0 | $0 | 0.00% | −434,026−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −103,243−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −70,850−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −33,448−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −33,095−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −31,084−100.0% | Sold out |
| Velan Capital Investment Management LP | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −16,368−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −12,861−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −12,621−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −10,958−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −10,710−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −88−100.0% | Sold out |
| Sofos Investments, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |